PYC Therapeutics Starts Phase 1b Multiple Ascending Dose Study in Polycystic Kidney Disease; Shares Up Nearly 5%
MT Newswires Live
May 07
PYC Therapeutics (ASX:PYC) started a phase 1b multiple ascending dose study in patients with polycystic kidney disease, with the dosing of the first patient with its drug candidate, PYC-003, completed, according to a Thursday Australian bourse filing.
The study will seek to determine the safety/tolerability profile and optimal repeat dosing regimen of PYC-003 before a proposed transition to a registrational combined phase 2/3 trial.
It will also measure other endpoints, including urinary PC1 protein levels, total kidney volume on magnetic resonance imaging, and the estimated glomerular filtration rate, per the filing.
The company's shares gained nearly 5% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.